Investors & Media Press Releases
Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
Axovant Gene Therapies is a clinical-stage company focused on developing a pipeline of innovative gene therapy product candidates for debilitating neurological diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease.
Media and Investor Contact:
Source: Axovant Sciences Ltd.